A Double Blind, Placebo Controlled Two-part Study to Investigate the Dose-ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome

Trial Profile

A Double Blind, Placebo Controlled Two-part Study to Investigate the Dose-ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2017

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Dravet syndrome
  • Focus Adverse reactions; Registrational
  • Acronyms GWPCARE1
  • Sponsors GW Pharmaceuticals
  • Most Recent Events

    • 05 Dec 2016 According to a GW Pharmaceuticals media release, data from this trial presented at the 70th Annual Meeting of the American Epilepsy Society 2016.
    • 05 Dec 2016 Results published in the GW Pharmaceuticals Media Release
    • 26 Sep 2016 According to a GW Pharmaceuticals media release, the company plans to submit a NDA for cannabidiol (Epidiolex) to the US FDA in the first half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top